Ephedrine

(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol

Overview

Ephedrine belongs to Stimulants.

Key safety note: Ephedrine is a potent cardiovascular stimulant with a narrow margin between its therapeutic and toxic effects.[2]
Effects
Subjective effects vary. What a substance feels like depends on dose, individual physiology, mindset, and setting. The points below describe commonly reported effects, not guaranteed, uniform, or desirable outcomes.
    Dosing & duration
    Harm-reduction note: These are commonly cited reference ranges, not a recommendation or a “safe” dose. Potency, purity, body chemistry, tolerance, and drug combinations vary widely. Start low, go slow, wait for full effects before redosing, and never assume an unknown product matches these figures. Missing data is not evidence of safety.

    Not reported

    Dose ranges

    Duration

    Chemical & Physical Properties
    FormulaC10H15NO
    Molar mass165.23 g/mol
    StateSolid
    Melting point34 °C
    Boiling point255 °C
    Density1.0085 g/cm³ at 22 °C
    Vapor pressureNot reported
    pKa9.61
    LogP1.13
    SolubilityVery soluble in water (~56,900 mg/L at 25 °C, 63,600 mg/L at 30 °C), Soluble in oils
    Refractive indexNot reported
    Identifiers & Synonyms
    CAS299-42-3
    CAS (enantiomer)
    PubChem CID9294
    InChIKeyKWGRBVOPPLSCSI-WPRPVWTQSA-N
    InChIInChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1
    SMILESCN[C@@H](C)[C@H](O)c1ccccc1

    Synonyms

    • L-ephedrine
    • (−)-ephedrine
    • Ephedrine hydrochloride
    Pharmacodynamics & Biochemistry

    Ephedrine is a naturally occurring sympathomimetic alkaloid (from Ephedra / má huáng) and a mixed-acting amine. It works mainly indirectly: taken up into noradrenergic nerve terminals by the norepinephrine transporter, it displaces norepinephrine from storage vesicles into the synapse, raising adrenergic tone throughout the body: its most potent measured action is as a norepinephrine-transporter (NET) substrate (EC50 ≈50 nM), with weaker substrate activity at the dopamine transporter. Direct receptor activity is comparatively negligible: a receptorome screen found only weak binding at α2-adrenergic and 5-HT7 receptors (Ki ≈1–10 µM) and no meaningful α1- or β-adrenoceptor activity, so its sympathomimetic effects are essentially all indirect, via the noradrenaline it releases. Because release rather than direct receptor potency drives the effect, tolerance (tachyphylaxis) develops as vesicular stores deplete. The result is a broad sympathomimetic profile: α1-mediated vasoconstriction raises blood pressure and shrinks nasal mucosa (decongestion). β1 stimulation increases heart rate and cardiac output. β2 stimulation relaxes bronchial smooth muscle (bronchodilation). It crosses into the CNS and is a mild stimulant: less potent and less euphoric than amphetamine, to which it is structurally related and for which it is a synthesis precursor. The medicinal drug is the (1R,2S)-(−)-erythro isomer (L-ephedrine). Its diastereomer pseudoephedrine (1S,2S) shares the peripheral decongestant use but has weaker central and pressor effects. Ephedrine is largely excreted unchanged by the kidneys, so its clearance depends on urine pH: acidic urine speeds elimination and shortens its action.

    Biological targets

    • NET
    • Adrenergic system

    Binding & functional measurements

    TargetMeasurementSpecies
    Norepinephrine transporterpEC50 7.3Human
    β2-adrenoceptorpKi 5.6Human
    α2-adrenoceptorpKi 5.5Human
    5-HT7 receptorpKi 5.5Human
    Pharmacokinetics
    Bioavailability≈85–90% oral
    Tmax≈1–2 h (oral), onset 15–60 min oral, seconds IV
    Half-life≈3–6 h (shorter in acidic urine)
    VdNot reported
    Protein binding≈24–29%
    MetabolismMinimal hepatic (N-demethylation, oxidative deamination)
    ExcretionMainly renal, ~55–75% unchanged. Strongly urine-pH dependent
    Toxicology & Safety
    Harm-reduction note: Toxicity and risk depend on dose, route, purity, combinations, setting, and individual health factors. Missing harms should never be interpreted as evidence of safety.

    Not reported

    Ephedrine is a potent cardiovascular stimulant with a narrow margin between its therapeutic and toxic effects. Common effects are a raised heart rate and blood pressure, palpitations, tremor, anxiety, insomnia, headache and urinary retention. Higher doses can cause dangerous hypertension, tachyarrhythmias, myocardial infarction, stroke, seizures and stimulant psychosis. Risk rises sharply when it is combined with other stimulants: the ephedrine + caffeine ('ECA') combination popular for weight loss and 'energy' markedly increases cardiovascular strain, and combining it with an MAO inhibitor can trigger a hypertensive crisis. Deaths linked to ephedra/ephedrine weight-loss supplements led the US FDA to ban them in 2004. It should be avoided in people with heart disease, hypertension, hyperthyroidism, phaeochromocytoma or closed-angle glaucoma.[2]

    Legal Status
    Legal note: Legal status can change over time and may vary by country, region, formulation, analogue status, prescription context, and enforcement practice. Always confirm with current official sources before relying on this section.
    Interactions & Contraindications

    Drug interactions

    MAOIs Risk of a severe hypertensive crisis, the combination is contraindicated.[2]
    Stimulants (amphetamines, cocaine), Caffeine Additive tachycardia, hypertension and arrhythmia risk, the ephedrine plus caffeine (ECA) combination is especially hard on the cardiovascular system.[2]
    Non-selective beta-blockers, Antihypertensive drugs Non-selective beta-blockers leave alpha-mediated vasoconstriction unopposed (hypertensive response), other antihypertensives may be antagonised.[2]
    Arrhythmogenic drugs (digoxin, TCAs, halogenated anaesthetics) Halogenated general anaesthetics, digoxin and tricyclic antidepressants increase the risk of cardiac arrhythmias.[2]
    Urinary acidifiers or alkalinisers Acidifiers speed elimination and shorten the effect, alkalinisers prolong it.[2]

    Contraindications

    Cardiovascular disease, hypertension or arrhythmia coronary artery disease, arrhythmia or uncontrolled hypertension.[2]
    Hyperthyroidism also phaeochromocytoma.[2]
    Concurrent MAOI, SSRI/SNRI or other serotonergic medication concurrent or recent (within 14 days) MAO-inhibitor use.[2]
    Closed-angle glaucoma closed-angle, and caution with prostatic hypertrophy or urinary retention.[2]
    Pregnancy or breastfeeding except where clearly indicated under medical supervision.[2]
    Usage & Context
    • Therapeutic.
    • Research.
    Sources & Evidence

    Further Information